Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Non-Current Deffered Revenue (2019 - 2025)

AVITA Medical's Non-Current Deffered Revenue history spans 7 years, with the latest figure at $290000.0 for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 10.49% year-over-year to $290000.0; the TTM value through Dec 2025 reached $290000.0, down 10.49%, while the annual FY2025 figure was $290000.0, 10.49% down from the prior year.
  • Non-Current Deffered Revenue reached $290000.0 in Q4 2025 per RCEL's latest filing, down from $298000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.1 million in Q2 2021 to a low of $290000.0 in Q4 2025.
  • Average Non-Current Deffered Revenue over 5 years is $560850.0, with a median of $369500.0 recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 152.87% in 2021, then plummeted 56.69% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $952000.0 in 2021, then dropped by 26.68% to $698000.0 in 2022, then crashed by 48.85% to $357000.0 in 2023, then decreased by 9.24% to $324000.0 in 2024, then fell by 10.49% to $290000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Non-Current Deffered Revenue are $290000.0 (Q4 2025), $298000.0 (Q3 2025), and $307000.0 (Q2 2025).